Christopher J. Nirschl

4.2k total citations · 1 hit paper
31 papers, 1.7k citations indexed

About

Christopher J. Nirschl is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Christopher J. Nirschl has authored 31 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 19 papers in Immunology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Christopher J. Nirschl's work include Cancer Immunotherapy and Biomarkers (16 papers), Immunotherapy and Immune Responses (13 papers) and CAR-T cell therapy research (12 papers). Christopher J. Nirschl is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Immunotherapy and Immune Responses (13 papers) and CAR-T cell therapy research (12 papers). Christopher J. Nirschl collaborates with scholars based in United States, Israel and South Korea. Christopher J. Nirschl's co-authors include Charles G. Drake, Christina M. Kochel, Thomas R. Nirschl, Brian J. Francica, Esteban Velarde, Andrew B. Sharabi, Theodore L. DeWeese, Nicholas M. Durham, Robert A. Anders and Christopher M. Jackson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Christopher J. Nirschl

30 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

2014 510 citations Andrew B. Sharabi, Christopher J. Nirschl et al. Cancer Immunology Research profile →

Peers

Countries citing papers authored by Christopher J. Nirschl

Since Specialization

Citations

This map shows the geographic impact of Christopher J. Nirschl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher J. Nirschl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher J. Nirschl more than expected).

Fields of papers citing papers by Christopher J. Nirschl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher J. Nirschl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher J. Nirschl. The network helps show where Christopher J. Nirschl may publish in the future.

Co-authorship network of co-authors of Christopher J. Nirschl

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher J. Nirschl. A scholar is included among the top collaborators of Christopher J. Nirschl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher J. Nirschl. Christopher J. Nirschl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab. 2024 ·Journal of Clinical Oncology ·Justin C. Moser, Mateusz Opyrchal, (unknown), Brendan D. Curti, Igor Puzanov, Jeffrey A. Sosman, Mehmet Asım Bilen, Kristin Morris, Christopher J. Nirschl, (unknown), (unknown), (unknown), Kulandayan K. Subramanian, Oliver Schönborn‐Kellenberger, Sameer Chopra, Randi Isaacs	2
2	mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity 2023 ·Cancer Immunology Research ·Christopher J. Nirschl, (unknown), (unknown), Connor J. Dwyer, Daniel J. Hicklin, (unknown), Cynthia Seidel‐Dugan, (unknown), (unknown), Jenna M. Sullivan, William M. Winston, Andrés Salmerón	8
3	737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors 2023 ·SHILAP Revista de lepidopterología ·Justin C. Moser, Mateusz Opyrchal, (unknown), Mehmet Asım Bilen, Brendan D. Curti, Igor Puzanov, Kristin Morris, Christopher J. Nirschl, (unknown), (unknown), (unknown), Kulandayan K. Subramanian, Sameer Chopra, (unknown)	2
4	An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes 2022 ·Cancer Cell ·(unknown), Akanksha Verma, Ruth Dannenfelser, Marit M. Melssen, Itay Tirosh, Benjamin Izar, Tae‐Gyun Kim, Christopher J. Nirschl, K. Sanjana P. Devi, Walter C. Olson, Craig L. Slingluff, Víctor H. Engelhard, Levi A. Garraway, Aviv Regev, Kira Minkis, Charles H. Yoon, Olga G. Troyanskaya, Olivier Elemento, Mayte Suárez‐Fariñas, Niroshana Anandasabapathy	39
5	Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody 2021 ·Cancer Treatment and Research Communications ·Kenna Shirasuna, Gerald Koelsch, Cynthia Seidel‐Dugan, Andrés Salmerón, Philipp Steiner, William M. Winston, (unknown), Christopher J. Nirschl, (unknown), (unknown), (unknown), (unknown), Masahiro Takeuchi, Daniel J. Hicklin, Taku Yoshida	10
6	723 WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models 2021 ·SHILAP Revista de lepidopterología ·Ethika Tyagi, (unknown), (unknown), Dan Hicklin, Nesreen S. Ismail, Kristin Morris, Christopher J. Nirschl, Andrés Salmerón, (unknown), Philipp Steiner, (unknown), Jenna M. Sullivan, William M. Winston	3
7	Abstract 1716: WTX-330, a conditionally activated IL-12 INDUKINE, releases IL-12 selectively in the tumor microenvironment to activate anti-tumor immune responses and induce regressions in mouse tumor models 2021 ·Cancer Research ·Philipp Steiner, (unknown), Dan Hicklin, Nesreen S. Ismail, Kristin Morris, Christopher J. Nirschl, Andrés Salmerón, (unknown), (unknown), Jenna M. Sullivan, William M. Winston	4
8	Conditionally Activated IL-12 or IFNα Indukine™ Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-Human Primates 2021 ·Blood ·Philipp Steiner, (unknown), (unknown), Daniel J. Hicklin, Randi Isaacs, Nesreen S. Ismail, Kristin Morris, Christopher J. Nirschl, Andrés Salmerón, (unknown), (unknown), Jenna M. Sullivan, Ethika Tyagi, William M. Winston	9
9	PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF 2018 ·Cancer Immunology Research ·Girija Goyal, Karrie Wong, Christopher J. Nirschl, Nicholas Souders, Donna Neuberg, Niroshana Anandasabapathy, Glenn Dranoff	27
10	Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo 2017 ·International Immunopharmacology ·(unknown), Jeremy B. Foote, James M. Leatherman, Justin P. Edwards, Todd D. Armstrong, Christopher J. Nirschl, Jessica Hicks, Leisha A. Emens	31
11	Duality at the gate: Skin dendritic cells as mediators of vaccine immunity and tolerance 2016 ·Human Vaccines & Immunotherapeutics ·Christopher J. Nirschl, Niroshana Anandasabapathy	9
12	Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination 2015 ·Clinical Cancer Research ·Christopher M. Jackson, Christina M. Kochel, Christopher J. Nirschl, Nicholas M. Durham, Jacob Ruzevick, Angela Alme, Brian J. Francica, (unknown), Andrew Daniels, Thomas W. Dubensky, Peter Lauer, Dirk G. Brockstedt, Emily G. Baxi, Peter A. Calabresi, Janis M. Taube, Carlos A. Pardo, Henry Brem, Drew M. Pardoll, Michael Lim, Charles G. Drake	54
13	Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance 2015 ·Prostate Cancer and Prostatic Diseases ·Allison Martin, Thomas R. Nirschl, Christopher J. Nirschl, Brian J. Francica, Christina M. Kochel, Adrie van Bokhoven, Alan K. Meeker, M. Scott Lucia, Robert A. Anders, Angelo M. De Marzo, Charles G. Drake	142
14	Abstract 267: Combining androgen deprivation with immune checkpoint blockade delays the development of castration resistance in a murine model of prostate cancer 2015 ·Cancer Research ·Ying‐Chun Shen, Christina M. Kochel, Brian J. Francica, Angela Alme, Christopher J. Nirschl, Thomas R. Nirschl, Zoila A. Lopez‐Bujanda, (unknown), Mark Selby, Alan J. Korman, Charles G. Drake	2
15	Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen breakdown → 2014 ·Cancer Immunology Research ·Andrew B. Sharabi, Christopher J. Nirschl, Christina M. Kochel, Thomas R. Nirschl, Brian J. Francica, Esteban Velarde, Theodore L. DeWeese, Charles G. Drake	510
16	Oncogenic Kras Activates a Hematopoietic-to-Epithelial IL-17 Signaling Axis in Preinvasive Pancreatic Neoplasia 2014 ·Cancer Cell ·Florencia McAllister, Jennifer M. Bailey, Janivette Alsina, Christopher J. Nirschl, Rajni Sharma, Hongni Fan, Yanique Rattigan, Jeffrey C. Roeser, (unknown), Hao Zhang, Elizabeth M. Jaffee, Charles G. Drake, Franck Housseau, Anirban Maitra, Jay K. Kolls, Cynthia L. Sears, Drew M. Pardoll, Steven D. Leach	305
17	Sustained CD4⁺T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide 2014 ·OncoImmunology ·Susannah G. Ellsworth, Ani Sarkis Balmanoukian, Ferdynand Kos, Christopher J. Nirschl, Thomas R. Nirschl, Stuart A. Grossman, Leo Luznik, Charles G. Drake	58
18	Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo 2014 ·PLoS ONE ·Nicholas M. Durham, Christopher J. Nirschl, Christopher M. Jackson, (unknown), Christina M. Kochel, Robert A. Anders, Charles G. Drake	143
19	Role of Radiation Therapy in Inducing Antigen Specific Antitumor Immune Responses When Combined With Anti-PD1 Checkpoint Blockade: Mechanism and Clinical Implications 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Andrew B. Sharabi, Christopher J. Nirschl, (unknown), Thomas R. Nirschl, Brian J. Francica, Angela Alme, Esteban Velarde, (unknown), Charles G. Drake	7
20	Expression of neuropilin-1 on in vivo induced regulatory T cells 2013 ·Journal for ImmunoTherapy of Cancer ·Christopher J. Nirschl, Christina Ceccato, Angela Alme, Brian J. Francica, Charles G. Drake	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact